[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511178":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":21,"armGroups":31,"interventions":44,"overallOfficials":21,"centralContacts":21,"locations":21,"responsibleParty":58,"collaborators":62,"id":65,"slug":21,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":21,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":21,"overallStatus":84,"whyStopped":21,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":21},{"fullName":5,"class":6},"Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":21},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Changes in Visual Analogue scale (VAS)","The pain VAS is a unidimensional measure of pain intensity, used to record patients' pain progression, or compare pain severity between paints with similar conditions. Score ranges from 1 to 10, where 1 means lowest pain and 10 relates to highest pain","30 months (day 0, day 1, month 1, month 3, month 6, year 1 and year 2",{"measure":14,"description":15,"timeFrame":16},"Changes in Knee Injury and Osteoarthritis Outcome Score (KOOS)","KOOS reflects the individual disease burden and overall joint health. KOOS consists of 5 subscales; Pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport\u002FRec) and knee related Quality of life (QOL). The previous week is the time period considered when answering the questions. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale","30 months (day 0, month 3, month 6, year 1 and year 2)",{"measure":18,"description":19,"timeFrame":20},"Radiological changes in Magnetic resonance observation of cartilage repair tissue (MOCART 2.0)","MOCART score was introduced based on 7 pertinent variables that facilitate a standardized, reproducible, semiquantitative approach for the morphological assessment of cartilage repair. Variables assesed in MOCART are: 1. Degree of cartilage defect; 2. integration into adjacent cartilage; 3. surface of the repair tissue; 4. structure of the repair tissue; 5. signal intensity of repaired tissue; 6. bony defect or bony overgrowth; 7. subchondral changes. The score ranges between 0 and 100, being 100 the maximum level of tissue compromise","30 Months (day 0, year 1 and year 2)",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":21,"primaryPurpose":25,"observationalModel":21,"timePerspective":21,"maskingInfo":26},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":27,"maskingDescription":21,"whoMasked":28},"DOUBLE",[29,30],"PARTICIPANT","INVESTIGATOR",[32,38],{"label":33,"type":34,"description":35,"interventionNames":36},"IMUNOCEM","EXPERIMENTAL","Administration of umbilical cord-derived mesenchymal stromal cells suspension",[37],"Biological: INMUNOCEM",{"label":39,"type":40,"description":41,"interventionNames":42},"PLASMALYTE","PLACEBO_COMPARATOR","Administration of plasmalyte as vehicle for MSC",[43],"Drug: PLACEBO COMPARATOR",[45,52],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"BIOLOGICAL","INMUNOCEM","Mesenchymal Stromal Cell suspension intraarticularly injected",[33],[51],"Mesenchymal stromal cell suspension",{"type":53,"name":54,"description":55,"armGroupLabels":56,"otherNames":57},"DRUG","PLACEBO COMPARATOR","Administration of plasmalyte as a vehicle for MSC",[39],[39],{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","GUSTAVO SALGUERO","Research Leader Advanced Therapies Unit",[63],{"name":64,"class":6},"Hospital Infantil Universitario de San Jose","100511178",false,"NCT05936060","Cartilage Recovery in Adults With Knee Osteorthritis by Mesenchymal Cell Therapy: Randomized Trial of Radiologic and Clinical Outcomes","Recovery of Joint Cartilage in Adults With Knee Osteoarthritis by Use of Mesenchymal Stromal Cells Derived From Human Umbilical Cord: Randomized Controlled Clinal Trial With Clinical and Radiologic Outcomes","INMUNOCEM-OA","Inclusion Criteria:\n\nPain most days for the last month. Presence of osteophytes. Synovial fluid with mechanical characteristics. Morning stiffness for less than 30 minutes in the affected joint. Patellar crepitus. Patients aged 40 years or older and less than 60 years. Radiological criteria for osteoarthritis of the knee Kellgren-Lawrence 2 to 4 in comparative radiographs with knee support taken in the last 12 months prior to consultation.\n\nPain in one or both knees according to a visual analogue scale of 5 or more, out of 10 points in the last 3 months.\n\nExclusion Criteria:\n\nConsumption of non-steroidal anti-inflammatory drugs or anticoagulants in the last 14 days.\n\nPatient with a history of joint infiltration or arthroscopic surgery of the affected knee in the last 6 months.\n\nParticipants in another treatment or research study within the past year. Pregnant or lactating patients. Patient with active tumor pathology or a history of oncological disease. Patient with metabolic disease and\u002For uncontrolled coagulopathy at the assessment time.\n\nPatients who have received previous treatments such as microfractures, and osteochondral allografts.\n\nPatients with present meniscal lesions. Patients with a history of thyroiditis or thyroid nodules with increased antithyroglobulin antibodies.\n\nPatients with a history of osteoarticular infection in the last 5 years or active at the time of assessment.","ALL","40 Years","60 Years",{"count":76,"type":77},32,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","The treatment of osteoarthritis (OA) of the knee remains still controversial. Despite that fact advanced stages with symptomatic and functional improvement are obtained with total knee replacement, however, there is no treatment that neither modifies the natural history of this disease, nor avoid joint replacement surgery in young patients in whom the prosthesis has conflictive indications. Moreover, prosthetic surgery leads to lower long-term survival and in older patients, higher morbidity and mortality. Cell therapy promises to be a treatment option through the use of mesenchymal cells with the capacity control inflammatory responses and trigger the differentiation into chondrocytes. Here we propose a randomized placebo-controlled clinical trial to evaluate radiologic and clinical outcomes in patients with knee OA.",[83],"Knee Osteoarthritis","NOT_YET_RECRUITING","2023-06-29",{"date":87,"type":88},"2023-07-07","ACTUAL",{"date":90,"type":77},"2023-10-01",{"date":92,"type":77},"2026-07-31",{"name":60,"class":6}]